Why the study?
Does celecoxib reduce the incidence of endoscopically documented gastroduodenal ulcers compared to non-selective NSAIDs or placebo in patients with arthritis?
Does celecoxib reduce the incidence of endoscopically documented gastroduodenal ulcers compared to non-selective NSAIDs or placebo in patients with arthritis?
Celecoxib is associated with a significantly lower incidence of endoscopically documented gastroduodenal ulcers compared to non-selective NSAIDs like naproxen, diclofenac, and ibuprofen in arthritis patients.
No takes yet. Share an insight, caveat, or question.
Supports celecoxib over naproxen to reduce endoscopic ulcers in arthritis; confirms COX-2 selectivity GI benefits in Level 1 evidence.
Ashcroft et al. (2001) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: